Blueprint Medicines to Present Proof-of-Concept Data from Ongoing Phase 1 Clinical Trial of BLU-667 in Patients with RET-Altered Solid Tumors in a Clinical Trials Plenary Session at AACR Annual Meeting 2018

March 14, 2018

Responsive image

CAMBRIDGE, Mass., March 14, 2018 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ:BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that preliminary data from its Phase 1 clinical trial evaluating…

Category: Precious Metals